DOI QR코드

DOI QR Code

Predictors of pathologic complete response after preoperative concurrent chemoradiotherapy of rectal cancer: a single center experience

  • Choi, Euncheol (Proton Therapy Center, National Cancer Center) ;
  • Kim, Jin Hee (Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine) ;
  • Kim, Ok Bae (Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine) ;
  • Kim, Mi Young (Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine) ;
  • Oh, Young Ki (Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine) ;
  • Baek, Sung Gyu (Department of Colorectal Surgery, Dongsan Medical Center, Keimyung University School of Medicine)
  • 투고 : 2015.12.10
  • 심사 : 2016.05.10
  • 발행 : 2016.06.30

초록

Purpose: To identify possible predictors of pathologic complete response (pCR) of rectal cancer after preoperative concurrent chemoradiotherapy (CCRT). Materials and Methods: We conducted a retrospective review of 53 patients with rectal cancer who underwent preoperative CCRT followed by radical surgery at a single center between January 2007 and December 2012. The median radiotherapy dose to the pelvis was 54.0 Gy (range, 45.0 to 63.0 Gy). Five-fluorouracil-based chemotherapy was administered via continuous infusion with leucovorin. Results: The pCR rate was 20.8%. The downstaging rate was 66%. In univariate analyses, poor and undifferentiated tumors (p = 0.020) and an interval of ${\geq}7$ weeks from finishing CCRT to surgery (p = 0.040) were significantly associated with pCR, while female gender (p = 0.070), initial carcinoembryonic antigen concentration of <5.0 ng/dL (p = 0.100), and clinical stage T2 (p = 0.100) were marginally significant factors. In multivariate analysis, an interval of ${\geq}7$ weeks from finishing CCRT to surgery (odds ratio, 0.139; 95% confidence interval, 0.022 to 0.877; p = 0.036) was significantly associated with pCR, while stage T2 (odds ratio, 5.363; 95% confidence interval, 0.963 to 29.877; p = 0.055) was a marginally significant risk factor. Conclusion: We suggest that the interval from finishing CCRT to surgery is a predictor of pCR after preoperative CCRT in patients with rectal cancer. Stage T2 cancer may also be an important predictive factor. We hope to perform a robust study by collecting data during treatment to obtain more advanced results.

키워드

참고문헌

  1. Korea Central Cancer Registry. Annual report of cancer statistics in Korea in 2010. Goyang: Korea Central Cancer Registry; 2012.
  2. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-40. https://doi.org/10.1056/NEJMoa040694
  3. Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24:4620-5. https://doi.org/10.1200/JCO.2006.06.7629
  4. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355:1114-23. https://doi.org/10.1056/NEJMoa060829
  5. Roh MS, Colangelo LH, O'Connell MJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009;27:5124-30. https://doi.org/10.1200/JCO.2009.22.0467
  6. Park JH, Yoon SM, Yu CS, Kim JH, Kim TW, Kim JC. Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer. Cancer 2011;117:3703-12. https://doi.org/10.1002/cncr.25943
  7. Sasaki O, Atkin WS, Jass JR. Mucinous carcinoma of the rectum. Histopathology 1987;11:259-72. https://doi.org/10.1111/j.1365-2559.1987.tb02631.x
  8. Crucitti F, Sofo L, Doglietto GB, et al. Predictive factors in colorectal cancer: current status and new trends. J Surg Oncol Suppl 1991;2:76-82.
  9. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-46. https://doi.org/10.1056/NEJMoa010580
  10. Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 2004;22:1785-96. https://doi.org/10.1200/JCO.2004.08.173
  11. Rodel C, Martus P, Papadoupolos T, et al. Predictive significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005;23:8688-96. https://doi.org/10.1200/JCO.2005.02.1329
  12. Quirke P, Steele R, Monson J, et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 2009;373:821-8. https://doi.org/10.1016/S0140-6736(09)60485-2
  13. Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010;11:835-44. https://doi.org/10.1016/S1470-2045(10)70172-8
  14. Khan AA, Klonizakis M, Shabaan A, Glynne-Jones R. Association between pretreatment haemoglobin levels and morphometric characteristics of the tumour, response to neoadjuvant treatment and long-term outcomes in patients with locally advanced rectal cancers. Colorectal Dis 2013;15:1232-7. https://doi.org/10.1111/codi.12307
  15. Krauthamer M, Rouvinov K, Ariad S, et al. A study of inflammation-based predictors of tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Oncology 2013;85:27-32. https://doi.org/10.1159/000348385
  16. Carlomagno C, Pepe S, D'Armiento FP, et al. Predictive factors of complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer. Oncology 2010;78:369-75. https://doi.org/10.1159/000320464
  17. Chen MB, Wu XY, Yu R, et al. P53 status as a predictive biomarker for patients receiving neoadjuvant radiationbased treatment: a meta-analysis in rectal cancer. PLoS One 2012;7:e45388. https://doi.org/10.1371/journal.pone.0045388
  18. Lambrecht M, Vandecaveye V, De Keyzer F, et al. Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results. Int J Radiat Oncol Biol Phys 2012;82:863-70. https://doi.org/10.1016/j.ijrobp.2010.12.063
  19. Shanmugan S, Arrangoiz R, Nitzkorski JR, et al. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT. Ann Surg Oncol 2012;19:2178-85. https://doi.org/10.1245/s10434-012-2248-z
  20. Kim JW, Kim HC, Park JW, et al. Predictive value of (18)FDG PET-CT for tumour response in patients with locally advanced rectal cancer treated by preoperative chemoradiotherapy. Int J Colorectal Dis 2013;28:1217-24. https://doi.org/10.1007/s00384-013-1657-1
  21. Das P, Skibber JM, Rodriguez-Bigas MA, et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer 2007;109:1750-5. https://doi.org/10.1002/cncr.22625
  22. Wolthuis AM, Penninckx F, Haustermans K, et al. Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome. Ann Surg Oncol 2012;19:2833-41. https://doi.org/10.1245/s10434-012-2327-1
  23. Huh JW, Kim HR, Kim YJ. Clinical prediction of pathological complete response after preoperative chemoradiotherapy for rectal cancer. Dis Colon Rectum 2013;56:698-703. https://doi.org/10.1097/DCR.0b013e3182837e5b
  24. Restivo A, Zorcolo L, Cocco IM, et al. Elevated CEA levels and low distance of the tumor from the anal verge are predictors of incomplete response to chemoradiation in patients with rectal cancer. Ann Surg Oncol 2013;20:864-71. https://doi.org/10.1245/s10434-012-2669-8
  25. Pettersson D, Cedermark B, Holm T, et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg 2010;97:580-7. https://doi.org/10.1002/bjs.6914
  26. Latkauskas T, Pauzas H, Gineikiene I, et al. Initial results of a randomized controlled trial comparing clinical and pathological downstaging of rectal cancer after preoperative short-course radiotherapy or long-term chemoradiotherapy, both with delayed surgery. Colorectal Dis 2012;14:294-8. https://doi.org/10.1111/j.1463-1318.2011.02815.x

피인용 문헌

  1. Postoperative carcinoembryonic antigen level has a prognostic value for distant metastasis and survival in rectal cancer patients who receive preoperative chemoradiotherapy and curative surgery: a ret vol.33, pp.8, 2016, https://doi.org/10.1007/s10585-016-9818-6
  2. Clinical utility of pretreatment prediction of chemoradiotherapy response in rectal cancer: a review vol.8, pp.1, 2016, https://doi.org/10.1007/s13167-017-0082-x
  3. Clinical and Prognostic Significance of Pathological and Inflammatory Markers in Mucinous Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy and Curative Surgery vol.23, pp.None, 2017, https://doi.org/10.12659/msm.904116
  4. Difference in Tumor Area as a Predictor of a Pathological Complete Response for Patients With Locally Advanced Rectal Cancer vol.33, pp.6, 2017, https://doi.org/10.3393/ac.2017.33.6.219
  5. UEG Week 2018 Poster Presentations vol.6, pp.8, 2016, https://doi.org/10.1177/2050640618792819
  6. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in rectal cancer patients following neoadjuvant chemoradiotherapy vol.105, pp.5, 2016, https://doi.org/10.1177/0300891618792476
  7. Association Between Pathological Complete Response and Tumor Location in Patients with Rectal Cancer After Neoadjuvant Chemoradiotherapy, a Prospective Cohort Study vol.14, pp.5, 2016, https://doi.org/10.5812/ijcm.113135
  8. Clinical predictors of response to chemoradiotherapy for rectal cancer as an aid to organ preservation vol.91, pp.6, 2016, https://doi.org/10.1111/ans.16531